Abstract:Background: The risk of cardiovascular disease in type 1 diabetes remains extremely high, despite marked advances in blood glucose control and even the widespread use of cholesterol synthesis inhibitors. Thus, a deeper understanding of insulin regulation of cholesterol metabolism, and its disruption in type 1 diabetes, could reveal better treatment strategies. Methods: To define the mechanisms by which insulin controls plasma cholesterol levels, we knocked down the insulin receptor, FoxO1, and the key bile acid synthesis enzyme, CYP8B1. We measured bile acid composition, cholesterol absorption, and plasma cholesterol. In parallel, we measured markers of cholesterol absorption and synthesis in humans with type 1 diabetes treated with ezetimibe and simvastatin in a double-blind crossover study. Results: Mice with hepatic deletion of the insulin receptor showed marked increases in 12α-hydroxylated bile acids, cholesterol absorption, and plasma cholesterol. This phenotype was entirely reversed by hepatic deletion of FoxO1. FoxO1 is inhibited by insulin and required for the production of 12α-hydroxylated bile acids, which promote intestinal cholesterol absorption and suppress hepatic cholesterol synthesis. Knockdown of Cyp8b1 normalized 12α-hydroxylated bile acid levels and completely prevented hypercholesterolemia in mice with hepatic deletion of the insulin receptor (n=5-30), as well as mouse models of type 1 diabetes (n=5-22). In parallel, the cholesterol absorption inhibitor, ezetimibe, normalized cholesterol absorption and low-density lipoprotein cholesterol in patients with type 1 diabetes as well as, or better than, the cholesterol synthesis inhibitor, simvastatin (n=20). Conclusions: Insulin, by inhibiting FoxO1 in the liver, reduces 12α-hydroxylated bile acids, cholesterol absorption, and plasma cholesterol levels. Thus, type 1 diabetes leads to a unique set of derangements in cholesterol metabolism, with increased absorption rather than synthesis. These derangements are reversed by ezetimibe, but not statins, which are currently the first line of lipid-lowering treatment in type 1 diabetes. Taken together, these data suggest that a personalized approach to lipid lowering in type 1 diabetes may be more effective and highlight the need for further studies specifically in this group of patients.

Insulin Resistance Causes Posttranslational Downregulation of Hepatic Sortilin 1 in Diabetic Mice

Sortilin 1 Modulates Hepatic Cholesterol Lipotoxicity in Mice via Functional Interaction with Liver Carboxylesterase 1

Sortilin: A novel regulator in lipid metabolism and atherogenesis

Increased Carnitine Palmitoyl Transferase 1 Expression and Decreased Sterol Regulatory Element–binding Protein 1c Expression Are Associated with Reduced Intramuscular Triglyceride Accumulation after Insulin Therapy in High-Fat–diet and Streptozotocin-Induced Diabetic Rats

Transcriptional control of intestinal cholesterol absorption, adipose energy expenditure and lipid handling by Sortilin

Aberrant activation of liver X receptors impairs pancreatic beta cell function through upregulation of sterol regulatory element-binding protein 1c in mouse islets and rodent cell lines

Regulation Of Insulin Resistance And Adiponectin Signaling In Adipose Tissue By Liver X Receptor Activation Highlights A Cross-Talk With Ppar Gamma

The Role of Acyl-CoA Synthetase 1 in Bioactive Lipid Accumulation and the Development of Hepatic Insulin Resistance

Lipid Oversupply Induces CD36 Sarcolemmal Translocation Via Dual Modulation of PKCζ and TBC1D1: an Early Event Prior to Insulin Resistance

Hepatic Insulin/Snail1 Axis Protects Against Liver Steatosis and Insulin Resistance Through Epigenetically Suppressing Lipogenesis

Resistin Disrupts Glycogen Synthesis under High Insulin and High Glucose Levels by Down-Regulating the Hepatic Levels of GSK3β.

Insulin Decreases Myocardial Adiponectin Receptor 1 Expression Via PI3K/Akt and FoxO1 Pathway.

Insulin Resistance is Mechanistically Linked to Hepatic Mitochondrial Remodeling in Nonalcoholic Fatty Liver Disease.

Sortilin promotes macrophage cholesterol accumulation and aortic atherosclerosis through lysosomal degradation of ATP-binding cassette transporter A1 protein

Implications of Sortilin in Lipid Metabolism and Lipid Disorder Diseases

Insulin Prevents Hypercholesterolemia by Suppressing 12α-Hydroxylated Bile Acids

Hepatic miR‐125b inhibits insulin signaling pathway by targeting PIK3CD

Insulin receptors in vascular smooth muscle cells regulate plaque stability of atherosclerosis

Insulin resistance caused by lipotoxicity is related to oxidative stress and endoplasmic reticulum stress in LPL gene knockout heterozygous mice

Low-Density Lipoprotein Receptor-Related Protein-1 Protects Against Hepatic Insulin Resistance and Hepatic Steatosis

Sortilin-mediated translocation of mitochondrial ACSL1 impairs adipocyte thermogenesis and energy expenditure in male mice